Division of Angiotech Pharmaceuticals Inc.
Latest From Haemacure Corp.
Haemacure has put itself up for sale while its hunt for financing continues to be unsuccessful. The Canadian company, which has been seeking cash since the third quarter of last year, will also suspend development of its lead candidate and reduce costs.
The Canadian biotherapeutics company Haemacure has appointed Dr Thomas Lynch to its board of directors. Dr Lynch brings 15 years experience as a research scientist in public, academic and private sectors to the position, and whilst on the board will aid the progression to Phase II/III clinical trials for Haemacure's lead candidate, Hemaseel HMN (fibrin sealant), for biosurgical haemostasis. Dr Lynch currently serves as senior vice-president of compliance, regulatory affair and public policy for Talecris Biotherapeutics; prior to this he was vice-president of regulatory affair and quality assurance at CryoLife.
Renovo's scar-healing treatment Juvista (human recombinant TGF beta
Renovohas received positive feedback from the EU's CHMPregarding its plans for Phase III development of the scar-reduction treatment Juvista.
Surgical Equipment & Devices
- Surgical Sealants
- Therapeutic Areas
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
- Angiotech Pharmaceuticals Inc.
- Senior Management
Joseph Galli, CEO
Lyne Pare, Dir., Fin. & Admin.
- Contact Info
Phone: (514) 282-3350
215 Redfern Ave.
Montreal, H3Z 3L5
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.